Scarica l'app Stockscreener
0.00
100.00%
-1.17
Precedente Chiudi:
$1.17
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$30.65M
Reddito:
$16.45M
Utile/perdita netta:
$-14.11M
Rapporto P/E:
0.00
EPS:
0.84
Flusso di cassa netto:
$-11.46M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$3.3994
Ocuphire Pharma Inc Stock (OCUP) Company Profile
Nome
Ocuphire Pharma Inc
Settore
Industria
Telefono
248-681-9815
Indirizzo
37000 GRAND RIVER AVE., FARMINGTON HILLS
Confronta OCUP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCUP
Ocuphire Pharma Inc
|
0.00 | 30.65M | 16.45M | -14.11M | -11.46M | -0.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ocuphire Pharma Inc Stock (OCUP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-13 | Ripresa | H.C. Wainwright | Buy |
Ocuphire Pharma Inc Borsa (OCUP) Ultime notizie
Ocuphire Pharma Sets End-of-Phase 2 Meeting With FDA in Q4 to Discuss Diabetic Retinopathy Treatment - Marketscreener.com
Opus Genetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 - Marketscreener.com
Proliferative Diabetic Retinopathy Market Forecast: Growth Drivers and Future Directions Industry Overview,... - WhaTech
Opus Genetics, Inc. to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024 - Marketscreener.com
Opus Genetics president Benjamin Yerxa acquires $9,834 in stock - Investing.com India
Opus Genetics president Benjamin Yerxa acquires $9,834 in stock By Investing.com - Investing.com Canada
FY2024 EPS Estimates for Opus Genetics Cut by HC Wainwright - Defense World
IRD stock touches 52-week low at $1.07 amid market challenges - Investing.com India
Wainwright sets stock target on Opus Genetics, cites 2025 catalysts By Investing.com - Investing.com UK
Opus Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - Lelezard
Ocuphire Pharma Acquires Opus Genetics - Marketscreener.com
North Carolina gains public company with merger - The Business Journals
Ocuphire buys Opus Genetics, grows gene therapy pipeline - The Pharma Letter
Ocuphire Pharma Announces Acquisition of Opus Genetics - Vision Monday
Ocuphire Shares Rise After Extended US Patent For Nyxol Eye Drops Secured - Marketscreener.com
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal - AOL
Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics - Yahoo Finance
OCUP stock touches 52-week low at $1.14 amid market challenges - Investing.com UK
Ocuphire and Opus Genetics merge to develop IRD gene therapy - Yahoo! Voices
Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders - Business Wire
Ocuphire Pharma acquires Opus Genetics in all-stock deal By Investing.com - Investing.com Australia
Ocuphire Pharma acquires Opus Genetics - MSN
Wilson Sonsini Advises Opus Genetics on IP Matters Related to Acquisition by Ocuphire Pharma - Wilson Sonsini
Ocuphire Pharma acquires Opus Genetics in all-stock deal - Investing.com
Presbyopia Market on Track for Major Expansion by 2034, - openPR
Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight | Eyenovia, Orasis Pharma, Ocuphire Pharma, Novartis, Visus Therapeutics - The Globe and Mail
Mydriasis Market Forecasted to Surge in Coming Years, 2024-2034 - openPR
Ocuphire reports positive phase 3 results for eye treatment RYZUMVI - Investing.com
Ocuphire Pharma releases results from MIRA-2 and MIRA-3 clinical trials for phentolamine ophthalmic solution 0.75% for pharmacologically-induced mydriasis - Ophthalmology Times
Ocuphire reports positive phase 3 results for eye treatment RYZUMVI By Investing.com - Investing.com South Africa
Ocuphire Pharma Announces Publication of Full Phase 3 - GlobeNewswire
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology - StockTitan
OFS Credit Company, Inc. Prices Preferred Stock Offering - Business Wire
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
OFS Credit to offer preferred stock in public offering - MSN
Ratio Review: Analyzing Ocugen Inc (OCGN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Analyzing SOPHiA GENETICS (NASDAQ:SOPH) & Cyclo Therapeutics (NASDAQ:CYTH) - Defense World
Oaktree Specialty Lending director buys shares worth over $16,000 By Investing.com - Investing.com Canada
Is OCGN’s price to cash per share ratio a concern for investors? - US Post News
Option Care Health, Inc. (NASDAQ:OPCH) Position Increased by First Eagle Investment Management LLC - Defense World
Option Care Health, Inc. (NASDAQ:OPCH) Shares Sold by DekaBank Deutsche Girozentrale - Defense World
Halozyme's ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO™: A New Era in MS Treatment - BP Journal
Opaleye Management Inc. Increases Stake in Codexis Inc. - Yahoo Finance
All the Doctor Odyssey guest stars we know so far - Hidden Remote
Mydriasis Treatment Market Booming Worldwide With Leading Key - openPR
Full approval of PBC therapy Ocaliva rejected by FDA committee in 10-1 vote - Liver Disease News
American Century Companies Inc. Raises Position in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World
Roche’s injectable Ocrevus Zunovo granted FDA approval to treat relapsing and primary MS - PMLiVE
Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates - MSN
Ocuphire Pharma commences phase 3 trial for presbyopia treatment - Investing.com India
Ocuphire Pharma Inc Azioni (OCUP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ocuphire Pharma Inc Azioni (OCUP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Magrath George | Chief Executive Officer |
Nov 15 '24 |
Buy |
1.01 |
90,294 |
91,215 |
483,244 |
| Magrath George | Chief Executive Officer |
Nov 18 '24 |
Buy |
1.02 |
9,706 |
9,943 |
492,950 |
| Jayagopal Ashwath | Chief Scientific & Dev. Ofc. |
May 22 '24 |
Buy |
1.76 |
3,500 |
6,178 |
78,500 |
| Magrath George | Chief Executive Officer |
May 17 '24 |
Buy |
1.75 |
5,000 |
8,772 |
430,000 |
| SCHACHLE JOSEPH K | Chief Operating Officer |
Mar 21 '24 |
Buy |
2.05 |
2,000 |
4,100 |
2,000 |
| Jhaveri Nirav S. | Chief Financial Officer |
Mar 21 '24 |
Buy |
2.10 |
10,000 |
21,000 |
150,000 |
| Magrath George | Chief Executive Officer |
Mar 18 '24 |
Buy |
1.96 |
25,000 |
49,050 |
425,000 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):